Inhibikase stockholders re-elect directors, ratify auditor, approve equity plan amendment at 2025 annual meeting

Inhibikase Therapeutics, Inc.

Amit Munshi and David Canner re-elected as Class II directors with 56.8M and 57.7M votes for, respectively; 3.4M broker non-votes.
CohnReznick LLP ratified as independent auditor for FY2025: 61.1M votes for, 29k against, no broker non-votes.
Amendment to 2020 Equity Incentive Plan (evergreen provision) approved: 46.3M for, 11.4M against, 3.4M broker non-votes.
Annual meeting held June 27, 2025; no other matters voted on.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.